SYRE Nov 2024 22.500 put
| Previous Close | 2.0500 |
| Open | 2.0500 |
| Bid | 0.0000 |
| Ask | 5.0000 |
| Strike | 22.50 |
| Expire Date | 2024-11-15 |
| Day's Range | 2.0500 - 2.0500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 2 |
PR NewswireSpyre Therapeutics Announces Expected Acceleration of SPY003 (IL-23p19) Clinical Timelines and Presentations at UEGW supporting Spyre's Portfolio of Potentially Best-in-Class Antibodies and Combinations
Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of inflammatory bowel disease ("IBD"), today announced updated pipeline progress and timelines, as well as scientific presentations at the United European Gastroenterology Week ("UEGW") Congress.
- PR Newswire
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of Inflammatory Bowel Disease ("IBD"), today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grants of (i) stock options to purchase 400,000 shares of common stock of S
